INTRODUCTION
Human cathepsin D is a ubiquitous, lysosomal, aspartic endoproteinase that is proteolytically active at low pH. Cathepsin D is overproduced and abundantly secreted by human epithelial breast cancer cells (1, 2) with expression levels in breast cancer correlating with poor prognosis (3, 4) . Cathepsin D affects both cancer and stromal cells in the tumor microenvironment by increasing the proliferation of cancer cells (1, 5, 6) , stimulating fibroblast outgrowth (7, 8) , angiogenesis (5, 9) , and metastasis (10) . However, little is known of the molecular mechanisms involved or its substrates in these processes.
Human cathepsin D is synthesized as a 52-kDa precursor that is converted in the endosomes to an active, 48-kDa single-chain intermediate, and then to the fully active mature protease in the lysosomes. Mature human cathepsin D is composed of a 34-kDa heavy chain and a 14-kDa light chain. Its catalytic site includes two critical aspartic residues, residues 33 on the 14-kDa chain and 231 on the 34-kDa chain.
The over-production of cathepsin D by breast cancer cells leads to hypersecretion of the 52-kDa procathepsin D into the extracellular environment (1, 2) . Purified 52-kDa procathepsin D auto-activates in acidic conditions giving rise to a catalytically active 51-kDa pseudo-cathepsin D, which retains the 18 residues (27-44) of the prosegment (11) . While the extracellular environment is more acidic in tumors than in the corresponding normal tissues (12) (13) (14) , the question is whether it is sufficiently acidic for procathepsin D to cleave its pathophysiological substrates. If so, the identification of these substrates will be important for the mechanistic understanding of the role of this protease in cancer. 6 We show that procathepsin D secreted by breast cancer cells binds to cystatin C and specifically hydrolyses this cysteine protease (family C1) inhibitor. Cysteine cathepsins promote the proliferation, invasion, and metastasis of cancer cells (15, 16) suggesting a new unexplored link in the protease web (17, 18) . Using a degradomics approach known as terminal amine isotopic labelling of substrates (TAILS) (19, 20) , we found that the amount of cystatin C in the extracellular environment is reduced in a cathepsin D-dependent manner in the secretome of mouse embryonic fibroblasts (MEFs) derived from cathepsin D knock-out mice stably transfected with human cathepsin D compared to cathepsin D -/-MEFs. In particular, we show that procathepsin D secreted by breast cancer cells contributes to the protease web in the acidic tumor microenvironment by specific cleavages in cystatin C, thereby increasing cysteine cathepsin proteolytic activity.
MATERIALS AND METHODS

Yeast two-hybrid assay
Human cath-D was fused with the LexA DNA-binding domain of the pMW101 vector.
A cDNA library derived from normal breast tissue was cloned into the galactosidaseinducible pYESTrp2 vector (Invitrogen) containing a B42 activating domain. The yeast two-hybrid screen was performed as described previously (8) .
Plasmids
Human pcDNA3.1(-)cathepsin D expression plasmid has previously been described (8) . The full-length human cystatin C was sub-cloned from the pUC18 cystatin C plasmid into the HindIII and EcoR1 sites of the pcDNA3.1(+) vector (Invitrogen) to make pcDNA3.1(+)cystatin C. For GST pull-down, pGEX-4T-2cystatin C was generated by inserting PCR-amplified cDNA encoding human cystatin C (1-146) from pcDNA3.1(+)cystatin C into pGEX-4T-2 that had been digested by EcoRI and XhoI.
GST pull-down assay
[ 35 S]methionine-labeled procathepsin D was obtained by transcription and translation using the TNT T7 -coupled reticulocyte lysate system (Promega). GST and GSTcystatin C fusion proteins were produced in Escherichia coli B strain BL21 by incubation with isopropyl-1-thio--D-galactopyranoside (1 mM) for 3 h at 37°C. The GST fusion proteins were purified on glutathione-Sepharose beads (Amersham Biosciences). For pull-down assays, 20 µl bed volume of glutathione-Sepharose beads with immobilized GST fusion proteins were incubated overnight at 4°C with [ 35 S]methionine-labeled proteins in 500 µl PDB buffer (20 mM HEPES-KOH (pH 7.9), 8 10% glycerol, 100 mM KCl, 5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 0.2 mM phenylmethylsulfonylfluoride) containing 15 mg/ml BSA and 0.1% Tween 20. The beads were washed four times with 500 µl PDB buffer, and the eluted proteins were resolved by 15% SDS-PAGE, stained with Coomassie blue, and exposed to X-ray film.
Secretome preparation
Cathepsin D -/immortalized MEFs stably transfected with empty vector (CD55-/-SV40) or the cath-D expression vector encoding human pre-procathepsin D (CD55-/cath-D) were prepared as previously described (7) . MEF cells (6 T175 flasks per condition) grown to 80% confluence were washed extensively with phenol red-free, serum-free medium to remove serum proteins and grown overnight in phenol redfree, serum-free medium. Samples of conditioned medium were immediately treated with protease inhibitors (1 mM EDTA, protease inhibitor cocktail (Complete; Roche Applied Science)), clarified by centrifugation (5 min, 500 g; 30 min, 8,000 g) and filtered (0.45 µM). Conditioned medium proteins in 50 mM Hepes, pH 7.5 were then concentrated to 2 mg/ml by passage through Amicon filters (3 kDa cut-off, Millipore).
Enrichment and mass spectrometric analysis of protein N-termini
Protein N-terminal peptides were enriched using Terminal Amine Isotope Labeling of Substrates (TAILS) as described (19) using the option for isotopic labeling of proteins with iTRAQ reagents. Peptides were pre-fractionated by strong cation exchange chromatography and analysed by LC-MS/MS (QSTAR XL, Applied Biosystems).
Peptides were identified at the 95% confidence level from the human UniProtKB/Swissprot protein database (release date) using two search engines, 9 MASCOT v2.3 (Matrix Science) and X!TANDEM (21) , in conjunction with PeptideProphet (19) 0.12 mM) and cardiolipin (Sigma; 0.05 mM) were added in the reaction mixture for cleavage performed at higher pH according to (23) .
Degradation of extracellular cystatin C by secreted procathepsin D
Conditioned medium from MCF-7 cells was obtained by incubating cells for 24 h in DMEM without sodium bicarbonate buffered with 50 mM Hepes buffer (pH 7) in absence of FCS. The 24 h conditioned medium was then incubated, with or without pepstatin A (50 µM), at 37°C at pH 3.5 by acidification with 1N HCl, for up to 3 h. In other experiments, the 24 h conditioned medium was incubated, with or without pepstatin A (50 µM), at 37°C for 1 h at different pH values using Britton-Robinson buffer. The proteins in this treated medium (20 µl) were separated by 17% SDS-PAGE and immunoblotted for cystatin C using anti-cystatin C rabbit polyclonal antibody (DAKO).
Quantification of cysteine cathepsin activity
Conditioned media of MCF-7 cells silenced or not for cathepsin D and incubated at pH 3.5 for 10 min, or at pH 5.6 for 1 or 2 h were incubated in 100 mM sodium acetate buffer (pH 5.5) containing 4 mM DTT, 2 mM EDTA in the presence of Z-Phe-Arg-AMC (40 μM), and cysteine cathepsin proteolytic activity was monitored continuously for 120 min at exc=350 nm and em=460 nm (Gemini spectrofluorimeter, Molecular Devices, France). Controls were performed in the presence of the broad-spectrum cysteine cathepsin inhibitor, E-64 (10 µM), or the cathepsin B inhibitor, CA-074 (4 µM).
Immunoblotting of cysteine cathepsins
The goat anti-human cathepsin S was obtained from R&D Systems (Lille, France).
Other primary polyclonal antibodies were raised in rabbits: anti-human cathepsin B 
RESULTS
Cystatin C binds to procathepsin D secreted by breast cancer cells at neutral pH
We performed a yeast two-hybrid screening using a LexA DNA-binding domain fused to the 48-kDa intermediate human cathepsin D as bait, and a cDNA library isolated from normal human breast tissue to identify new molecules that interact with cathepsin D. The clone we isolated was 100% identical to amino acids 39-146 of cystatin C (Fig. 1A) . We then verified this interaction by GST pull-down experiments with full-length human cystatin C fused to GST (GST-cyst C) ( Fig. 1B, panel a) .
Procathepsin D was bound to GST-cyst C (Fig. 1B, panel b ), indicating that cystatin C interacts directly with procathepsin D.
Next we then co-transfected COS cells with cystatin C and procathepsin D expression vectors to determine whether procathepsin D interacted with cystatin C extracellularly. Upon incubation with an anti-cystatin C antibody, analysis of the conditioned medium from these cells showed that secreted 52-kDa procathepsin D was immunoprecipitated with 14-kDa cystatin C (Fig. 1C, panel a) . Reciprocally, incubation of the conditioned medium with anti-cathepsin D antibody showed that secreted cystatin C was immunoprecipitated along with procathepsin D (Fig. 1C , panel b). Thus, the procathepsin D and cystatin C co-transfected in COS cells interacted in the extracellular environment at neutral pH.
We confirmed this extracellular interaction between procathepsin D and cystatin C by studying the interaction of procathepsin D with the cystatin C secreted by NIH-
14
3T3 fibroblasts stably transfected with cathepsin D at neutral pH. Immunoaffinity purification of procathepsin D with an anti-cathepsin D antibody revealed that cystatin C copurified with procathepsin D (Fig. 1D, panel a) . This indicates that secreted cystatin C interacts with the procathepsin D synthesized by stably-transfected NIH-3T3 fibroblasts at neutral pH.
We screened cystatin C secretion in a variety of breast cancer cell lines to verify the extracellular interaction between procathepsin D and cystatin C (Fig. S1 ).
Cathepsin D is known to be over-produced and hypersecreted by breast cancer cells (1, 2) , and our survey revealed that all the breast cancer cell lines tested, except the BT20 cell line, secreted cystatin C (Fig. 1D , panel c). Lastly, since breast cancer cells synthesize and secrete procathepsin D and cystatin C, we investigated their interaction in the conditioned medium from MCF-7 breast cancer cells at neutral pH.
Again, cystatin C was purified together with procathepsin D (Fig. 1D, panel b ). We conclude that cystatin C and procathepsin D interact in secretome of MCF-7 breast cancer cells. We have thus shown that procathepsin D interacts directly with cystatin C in the extracellular space of breast cancer cells at neutral pH.
Identification of the extracellular proteins affected by a cathepsin D deficiency
We analysed the secreted proteome harvested from cathepsin D -/-MEFs stably transfected with empty vector (CD55-/-SV40) or human cathepsin D (CD55-/-cath-D)
vector by TAILS at neutral pH to determine the impact of cathepsin D on extracellular protein processing. We identified 746 unique N-terminal peptides from 569 unique proteins, and quantified 710 of the N-termini from 542 proteins ( Fig. 2A) . A threefold change was used as cut-off to determine N-termini substantially affected by cathepsin D activity, as in earlier TAILS studies (19, 24) . Based on this criterion, 22 neo-N termini were more abundant in cells producing cathepsin D than in cells transfected with the empty vector, while 48 mature protein N termini were reduced in abundance in the secretome of cathepsin D-transfected cells, indicating cleavage and loss of the peptide from cleaved or degraded protein (Table S1 ).
Notably,the N-terminus of mature cystatin C was 7-fold less abundant in the secretome of cathepsin D transfected cells (CD55-/-cath-D) compared to that of cathepsin D deficient cells (CD55-/-SV40) (Table S1 ). Furthermore, analysis of the transcriptome of C55-/-SV40 and C55-/-cath-D cells showed that the reduced cystatin C protein in the C55-/-cath-D secretome was not due to down-regulation of cystatin C gene expression in the presence of cathepsin D (Fig. 2B , Table S2 ). Thus, proteomics analysis shows that the amount of cystatin C in the extracellular environment is reduced in a cathepsin D-dependent manner.
Cleavage of cystatin C by human procathepsin D in vitro
We investigated the capacity of cathepsin D to cleave cystatin C in vitro at low pH. Recombinant 52-kDa human procathepsin D was auto-activated to 51-kDa proteolytically active enzyme (Fig. 3, panel a) and then incubated at pH 3.5 with recombinant human cystatin C. This resulted in extensive hydrolysis of cystatin C at 10 major and 3 minor cleavage sites ( Fig. 3, panel b ). The 10 major sites overlapped with the 4 cleavage sites described previously for 34+14-kDa mature human cathepsin D (25) . Pepstatin A, an inhibitor of aspartic proteases, inhibited the autoactivation of recombinant procathepsin D (Fig. 3, panel a) , and the cleavage of cystatin C (data not shown). Thus, procathepsin D degrades cystatin C in an acidic environment in vitro.
Degradation of cystatin C by cathepsin D secreted by breast cancer cells at acidic pH
Since the extracellular environment of tumors is acidic, we examined the capacity of procathepsin D interacting extracellularly with cystatin C to degrade it in the extracellular medium of breast cancer cells at low pH (Fig. 4) . The 52-kDa procathepsin D secreted in the conditioned medium of MCF-7 breast cancer cells was auto-activated into the 51-kDa proteolytically-active form at low pH (Fig. 4A , panel a), as was the recombinant purified procathepsin D (Fig. 3, panel a) . Cystatin C was hydrolysed in a time-dependent manner in the conditioned medium of MCF-7 breast cancer cells ( Fig. 4A, panel b ). Pepstatin A blocked cystatin C degradation, confirming the involvement of secreted aspartic protease proteolytic activity (Fig. 4A ,
We then assessed the capacity of procathepsin D to hydrolyse cystatin C at the extracellular pH 5.5 to 6.8, found within tumors (Fig. 4B, panel a) . The cystatin C secreted into the conditioned medium of MCF-7 cells was significantly degraded in a pH-dependent manner from pH 3.5 to pH 6.8 (Fig. 4B, panel b ). Hydrolysis of recombinant cystatin C also occurred with recombinant cathepsin D for acidic pH (3.6 to 6.2) ( Fig. S1 ). Lastly, we determined whether procathepsin D is the secreted aspartic protease responsible for the extracellular breakdown of cystatin C. We silenced cathepsin D expression in MCF-7 cells by RNA interference such that no extracellular procathepsin D was produced (Fig. 4C, panels a and c) . The silencing of cathepsin D synthesis led to decreased cystatin C degradation at pH 3.5 (Fig. 4C, panel b, bottom) in a time-dependent manner compared to Luc silencing (Fig. 4C, panel b, top) Similar results were obtained at pH 5.6 ( Fig. 4C, panel d) , confirming that procathepsin D is the secreted aspartic protease responsible for cystatin C hydrolysis under acidic conditions. Our findings therefore strongly suggest that the procathepsin D secreted by breast cancer cells breaks-down cystatin C in the acidic breast tumor micro-environment.
Cystatin C degradation by procathepsin D led to increased proteolytic activity of extracellular cysteine cathepsins in breast cancer cells
Since cystatin C is an extremely potent extracellular inhibitor of cysteine cathepsins, we investigated the effect of the extracellular hydrolysis of cystatin C by procathepsin D on the proteolytic activity of the extracellular cysteine cathepsins ( Fig.   5 ). We silenced cathepsin D synthesis in MCF-7 cells, which decreased the amounts of secreted procathepsin D (Fig. 5, panel Fig. 5, panel c, lane 1) . In the presence of pepstatin A, the break-down of cystatin C in the conditioned medium was abolished ( Fig. 5, panel b, lanes 2 and 4) , and the extracellular cysteine cathepsin proteolytic activity of these cells was significantly lower (Fig 5, panel c, lanes 2 and 4) , than that of Luc-transfected cells (Fig. 5, panel c, lane 1) (active cathepsins  40 nM as determined by E-64 titration).
In order to validate the functional relevance of this pathway at a pH that mimics the tumor microenvironment, we confirmed that extracellular hydrolysis of cystatin C at pH 5.6 in the extracellular medium of MCF-7 cells (Fig. 6, panel a) led to a significant increase of extracellular cysteine cathepsin proteolytic activity (Fig. 6,   panel b ). Among the different cysteine cathepsins detected in the conditioned medium of MCF-7 cells, we observed mainly mature cathepsin B (both single-chain and double-chain forms) whereas aminopeptidase cathepsin H, and cathepsins L, S and K were predominantly detected under their inactive pro-form ( Figure 6, panel c) .
CA-074 blocked ~60% of the proteolytic activity towards Z-Phe-Arg-AMC, indicating that the majority of this activity was due to cathepsin B (data not shown). We therefore conclude that secreted cathepsin D degrades cystatin C in an acidic environment, leading to increased proteolytic activity of extracellular cysteine cathepsins, such as cathepsin B in particular (Fig. 7) .
DISCUSSION
We show that cystatin C is both bound to procathepsin D secreted by breast cancer cells and is a substrate of the enzyme in the extracellular environment at a pH not normally associated with cathepsin D activity. Cystatin C is the most potent extracellular endogenous inhibitor of the cysteine cathepsins (15) inhibiting the growth and metastasis of many tumors (16, (26) (27) (28) . Several studies have suggested the therapeutic use of cystatin C and cysteine cathepsin inhibitors (26, (29) (30) (31) .
Cysteine cathepsins, such as cathepsin B and cathepsin L, are frequently missregulated in human cancers, and have been implicated in angiogenesis, proliferation, apoptosis, invasion and metastasis (15, 32) . Cysteine cathepsins are secreted into the extracellular milieu during cancer progression, where they take part in a vast multidimensional network of proteolytic interactions involving metalloproteases and serine proteases, rather than simply functioning individually (17, 33) . The complexity of the proteolytic activation cascade is enhanced by the presence of endogenous inhibitors specific for each class of proteases (16, 17) . Here, we have demonstrated that the procathepsin D secreted by breast cancer cells interacts extracellularly with cystatin C in secretome at neutral pH.
Secreted procathepsin D has been previously described to act as an extracellular binding protein in breast cancer, for example the low-density lipoprotein receptor-related protein-1 (LRP1) is a novel cathepsin D receptor on fibroblasts (8, 34) . Moreover, interaction of secreted prosaponin and procathepsin D also occurred in the breast cancer cell culture medium (35). Our TAILS experiments performed with the secretomes of cath-D -/-MEFs stably transfected with human cathepsin D or an empty vector showed that the amount of mature cystatin C in the extracellular environment was reduced in a cathepsin D-dependent manner, suggesting that cystatin C is a physiological substrate for cathepsin D. Earlier proteomic studies have
shown that cystatin C is also a substrate of matrix metalloproteinase 2 (MMP-2), being specifically inactivated upon one cleavage, so highlighting the complexity of the proteolytic cascades that are operating in the tumor microenvironment (36) .
We have now shown that procathepsin D extensively cleaves cystatin C in an acidic environment in vitro. The main peptide bonds cleaved by cathepsin D at low pH are Phe-Phe, Leu-Tyr, Tyr-Leu, and Phe-Tyr (37) , which agrees well with the cleavage sites identified in the present study. Notably, the sensitivity of the proteomics approach used meant that other cleavage sites were also detected.
Previous studies have shown that mature 34+14-kDa human cathepsin D inactivates in vitro at acidic pH different members of the cystatin family, such as stefin A, stefin B 20 and cystatin C (25, 38) . It was described that 34+14-kDa human cathepsin D cleaves human cystatin C into five fragments in vitro (25) , but this cleavage has never been previously demonstrated to occur ex cellulo. The procathepsin D cleavage sites we identified overlap those previously reported in other systems (25) . Our findings indicate that the break-down of cystatin C by procathepsin D also occurs in the conditioned medium of MCF-7 breast cancer cells in an acidic environment (pH 5.5 to 6.8), very like that frequently found in tumors due to the production of excess acid in hypoxic cells (12, 13, 39) . More recently, it was shown that cystatin C is a proteolytic target of cathepsin D in the commitment of hematopoietic stem cells to dendritic cells, indicating the relevance of this mechanism in other biological processes (40) .
In the present study, we describe an increase in the proteolytic activity of the cysteine cathepsins in the acidic conditioned medium of MCF-7 breast cancer cells that paralleled the hydrolysis of cystatin C by procathepsin D. Among the different cysteine cathepsins detected in the conditioned medium of MCF-7 cells, we observed mainly mature proteolytically active cathepsin B whereas aminopeptidase cathepsin H and cathepsins L, S and K were detected as proenzymes. It has been suggested that secreted procathepsin D directly activates the secreted procathepsin B in an acidic environment, converting it into its mature active form (41) . In this report, we confirmed that cathepsin B was well found mainly in mature form. Moreover, recent studies have indicated that the cysteine cathepsin-dependent invasiveness of tumors is linked to their proteolytic activity, and is enhanced in an acidic micro-environment (42) (43) (44) . Our present findings strongly suggest that the procathepsin D secreted by breast cancer cells is part of the protease web of the tumor acidic micro-environment, destroying cystatin C and so increasing cysteine cathepsin proteolytic activity, such as cathepsin B in particular.
This novel influence of secreted procathepsin D on the steady-state concentration of cystatin C may be crucial for tumor progression and metastasis.
Elucidating the networks of enzymatic activities that contribute to overall proteolysis during carcinogenesis may identify rate-limiting steps or pathways that could be targeted by anti-cancer treatment. 
